AVI BioPharma awarded contract to fight Marburg, Ebola

The U.S. Department of Defense Chemical and Biological Defense Program, part of the U.S. Army Space and Missile Defense Command, has awarded AVI BioPharma, Inc., a new contract for the development of Marburg and Ebola virus therapeutic candidates.

The contract, funded as part of the Transformational Medical Technologies Program, could potentially be worth as much as $291 million. It is comprised of four segments, with the first segment, to begin immediately, valued at $80 million.

The Transformational Medical Technologies program then has the option to continue to the next segment for each of the two therapeutic candidates. If all four segments are given the green light, the contract’s allowances would include all of the clinical and licensure activity that would be needed for the U.S. Food and Drug Administration to grant full regulatory approval and provide for the entire amount of the proposed funding.

AVI BioPharma, Inc., submitted its request for proposals in November 2009 and its proposals in February 2010. It opened its Investigational New Drug applications for both its Marburg and Ebola therapeutics under an earlier contract.

The Transformational Medical Technologies program was created by the Department of Defense to protect U.S. soldiers from emerging and genetically modified threats by creating a range of medical countermeasures to use against them, from research and development through testing.

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.